Awardee OrganizationUNIV OF NORTH CAROLINA CHAPEL HILL
Description
Abstract Text
It is proposed to investigate the role of the B cell in spontaneous
systemic autoimmunity in inbred mice by utilizing congenic mouse strains
which are homozygous at the lpr locus. These animals develop diffuse
lymphadenopathy and a variety of autoantibodies. Extensive previous work
has documented marked T-cell abnormalities in these mice. Their B cells
have been less carefully investigated: specifically, the role of the lpr
gene in the B cells and the role of the Ly-1+ B-cell subset are unknown.
The present proposal will address the function of the B cell in lpr-induced
autoimmunity in three specific ways: 1) It will determine the role of lpr
gene expression in B cells for autoantibody formation in lpr mice. 2) It
will explore the nature of T-B collaboration required for autoantibody
formation in lpr mice. 3) It will determine the role of Ly-1+ B cells in
autoantibody production in lpr mice. Experiments in all three areas will
rely on the generation of double-chimaeric mice in which the donor origin
of lymphocytes will be determined by immunoglobulin allotype or surface
phenotype markers. It will thus be possible to establish whether normal B
cells can be driven into autoantibody production in an lpr environment;
whether collaboration for autoantibody production in lpr mice is H-2
restricted; and what relative roles the Ly-1+ and conventional B-cell
subsets play in this disease. The latter issue will also be addressed by
sorting of autoantibody-forming cells. These studies will provide further
understanding of how B cells are induced to form autoantibodies in an
important murine model of SLE and should help to focus future research
toward the essential immunoregulatory abnormalities in this disease.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
DUNS Number
608195277
UEI
D3LHU66KBLD5
Project Start Date
30-June-1990
Project End Date
31-May-1994
Budget Start Date
01-June-1992
Budget End Date
31-May-1993
Project Funding Information for 1992
Total Funding
$148,705
Direct Costs
$102,910
Indirect Costs
$45,795
Year
Funding IC
FY Total Cost by IC
1992
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$148,705
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AR040620-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AR040620-03
Patents
No Patents information available for 5R01AR040620-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AR040620-03
Clinical Studies
No Clinical Studies information available for 5R01AR040620-03
News and More
Related News Releases
No news release information available for 5R01AR040620-03
History
No Historical information available for 5R01AR040620-03
Similar Projects
No Similar Projects information available for 5R01AR040620-03